Quick Facts

• Assists in the management of various partial- and full-thickness wounds.
• Provides support for the care of diabetic and venous ulcers.
• Facilitates the environment for healing in certain surgical and trauma wounds.

Helicol is a type of medical material that serves as a skin substitute to assist in the management of complex wounds. It provides appropriate support for the care of a variety of wound types where a temporary dressing or matrix is indicated.

Its uses include applications for certain partial-thickness and full-thickness wounds, such as pressure injuries and chronic vascular ulcers. The material also aids in the management of diabetic foot ulcers and venous leg ulcers. Additionally, it helps to support the care environment for certain trauma wounds, including abrasions and lacerations, and for surgical sites like donor and graft areas.

The application of this material is intended to promote the natural processes involved in tissue regeneration and wound closure, supporting the body’s response to injury. The use of the material is part of a comprehensive wound management strategy as determined by a healthcare professional.

Regulatory References

1. NIH MedlinePlus guidance on Wound Healing

Who can and cannot use Helicol? — Official Regulatory Information

The eligibility for using Helicol (Omeprazole) is strictly defined by regulatory guidelines based on population, age, and health status.

Contraindicated Populations

The medicine is contraindicated for patients with a known hypersensitivity to omeprazole, substituted benzimidazoles, or any component of the formulation. It is also forbidden for patients concurrently receiving the antiretroviral medicines nelfinavir or rilpivirine-containing products. Certain formulations are also contraindicated in patients with rare hereditary metabolic disorders like galactose intolerance.

Age-Related Eligibility

Use in pediatric patients younger than 1 year of age is not established. For children 1 year and older, eligibility is determined by specific indications and age thresholds. Dose adjustment is not needed for patients with impaired renal function or for older adults.

Conditional Restrictions

Caution is advised for patients with impaired hepatic function, where a lower daily dose may be sufficient. Furthermore, regulatory information requires that a healthcare professional must exclude the presence of gastric malignancy before commencing treatment for a gastric ulcer.

Pregnancy and Lactation Status

Based on available data, the medicine can be used during pregnancy. However, due to its excretion into breast milk, a decision must be made by a healthcare professional to discontinue nursing or discontinue the drug when used during lactation.

Interactions with other medicines and products

Helicol has documented restrictions against co-administration with several substances. The regulatory label advises against combining the product with the antiretrovirals Atazanavir and Nelfinavir due to a reduction in their plasma levels, which diminishes their efficacy. Co-administration with the anti-platelet agent Clopidogrel is also discouraged due to the risk of diminished pharmacological activity. Additionally, the strong enzyme inducers Rifampin and the herbal product St. John’s Wort should be avoided as they significantly decrease the concentration of Omeprazole.

The core basis for these interactions is pharmacokinetic. Omeprazole is officially recognized as an inhibitor of the CYP2C19 enzyme. This metabolic alteration results in the increased systemic exposure of co-administered CYP2C19 substrates, including Warfarin, Diazepam, and Cilostazol. Conversely, the product’s effect of sustained gastric acid suppression is a separate factor, as the elevated intragastric pH reduces the absorption of drugs that require an acidic environment, such as Ketoconazole and Iron Salts.

Caution is noted for drugs like Methotrexate and Tacrolimus, where co-administration may elevate and/or prolong serum concentrations. As a procedural constraint, the medicine must be temporarily discontinued at least 14 days before assessing Chromogranin A (CgA) levels, as the change in gastric pH interferes with this diagnostic test. The severity of some interactions may be heightened in patients identified as CYP2C19 poor metabolizers.

Helicol is an acid-labile pro-drug that selectively accumulates within the acidic secretory canaliculi of gastric parietal cells. In this low pH environment, the neutral pro-drug undergoes acid-catalyzed conversion to its active sulfonamide metabolite.

The active metabolite acts as a non-competitive, irreversible inhibitor of the H^+/ K^+-ATPase (the proton pump), which is the final common pathway for acid secretion. The sulfonamide forms a stable covalent disulfide bond with cysteine residues (specifically Cys813 and Cys892) located on the extracellular surface of the proton pump's alpha-subunit. This molecular interaction leads to the inactivation of the pump's ability to exchange intracellular H^+ for extracellular K^+. The downstream cascade is a substantial and long-lasting reduction in gastric acid secretion at the system level, directly modulating the pH within the gastric lumen.

Official Administration of Helicol (Omeprazole)

Helicol, which contains omeprazole, is administered primarily via the oral route in dosage forms such as delayed-release capsules or tablets in strengths of 10 mg, 20 mg, and 40 mg. An intravenous (IV) formulation is also indicated for administration in supervised clinical settings.

Dosing, Timing, and Administration

The standard administration pattern for Omeprazole necessitates that the oral dose be taken before eating (before a meal, ideally in the morning). This timing is crucial for aligning the drug's activity with its intended target. Due to the product's specialized delayed-release composition, the capsules or tablets must be swallowed whole with water. To ensure the protective coating is preserved and acid degradation is prevented, product labeling states that the pellets must not be crushed or chewed.

Standard adult dosing for most short-term courses, such as ulcer healing, ranges from 20 mg to 40 mg once daily. Higher daily doses, such as those exceeding 80 mg for pathological hypersecretory conditions, are required to be administered in divided doses (e.g., twice daily).

Population-Specific Instructions

Dose adjustments are generally not required for older adults or patients with renal impairment. However, standard labeling specifies that dose modification may be necessary for individuals with severe hepatic impairment (liver dysfunction). In these specific instances, a maximum daily dose of 10 mg to 20 mg may be sufficient.

Research Evidence / Overview of Studies for Helicol

This section summarizes the types of clinical research studies conducted for Helicol (Omeprazole), focusing on what researchers explored and what remains uncertain, based on official regulatory and scientific literature. The research described here provides context but does not offer individual predictions or clinical recommendations.

Evidence for Use in Gastroesophageal Reflux Disease (GERD)

Research examining Helicol for both erosive and non-erosive forms of GERD primarily consists of short-term randomized controlled trials (RCTs) and systematic reviews. This evidence was evaluated in studies monitoring the status of the esophageal lining and the frequency of patient-reported symptoms. Findings describe patterns observed in the studies over defined time intervals. Research highlights changes measured during the study period, exploring short-term symptom changes, particularly for outcomes related to physical discomfort like heartburn. Research provides limited insight into the management of individuals with atypical reflux symptoms. Furthermore, there is limited information for long-term outcomes regarding the optimal duration of use.

Evidence for Use in Peptic Ulcer Management

Helicol was evaluated in numerous RCTs and pooled analyses for its role in research on peptic ulcers. These studies focused on assessing outcomes linked to inflammatory or irritative states. The primary research goal was to evaluate the measurable status of ulcer lesions, monitored using endoscopy. Data show patterns related to changes in the status of ulcer lesions within typical 4- to 8-week treatment windows and the observed status of ulcers during follow-up maintenance periods. Research observes that outcomes often vary depending on concurrent strategies for underlying factors, such as H. pylori infection.

What is Still Uncertain About Helicol Research

Despite the large volume of research, several aspects of the evidence landscape are not fully established. Evidence quality varies across studies when moving from short-term healing outcomes to long-term surveillance. Long-term outcomes are not fully established for all physiological consequences of sustained acid suppression. Data for certain groups remain insufficient, including for various age groups within the pediatric population or for individuals with multiple complex health issues. The research cannot predict whether an individual will respond similarly to the group averages described in the findings.

Key Studies & References MedlinePlus Drug Information: Omeprazole

Common questions about Helicol (FAQ)

Q: What is Helicol used for?

A: Helicol is a combination medication indicated for the treatment of Helicobacter pylori infection and duodenal ulcer disease in certain patients. Its use is based on the official prescribing information approved by regulatory bodies.

Q: Can I stop taking Helicol once my symptoms improve?

A: The duration of treatment with Helicol is specified by the prescribing physician, typically based on established clinical guidelines for H. pylori eradication. Completing the full course of therapy, even if symptoms resolve, is generally considered important to maximize the chance of eliminating the infection.

Q: What should I do if I miss a dose of Helicol?

A: If a dose is missed, individuals should refer to the specific instructions provided by their pharmacist or healthcare provider. Product labeling generally advises against taking a double dose to compensate for a missed one.

Q: Are there any common side effects I should be aware of?

A: Like most medications, Helicol may be associated with side effects. Common reactions reported in clinical trials may include diarrhea, nausea, and taste disturbance. A patient should discuss any concerns about potential side effects with a healthcare professional.

The official requirements for storing and disposing of Helicol (Omeprazole) are mandated by regulatory authorities to ensure product stability and environmental safety.

Official Storage and Handling

Disposal Instructions

Unused or expired Helicol must be disposed of according to local requirements. It must not be thrown away via household waste or flushed down the sink or toilet, as mandated by environmental protection guidelines for pharmaceuticals. Patients are advised to utilize established drug take-back programs.